Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. It targets membrane-bound o-acyltransferase Porcupine and inhibits Wnt ligand palmitoylation, secretion, and pathway activation. RXC004 exhibits potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines and possesses multiple antitumor mechanisms.

Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. It targets membrane-bound o-acyltransferase Porcupine and inhibits Wnt ligand palmitoylation, secretion, and pathway activation. RXC004 exhibits potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines and possesses multiple antitumor mechanisms.

Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD.

Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD.

Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD.

Zandelisib(ME-401; PWT-143) is an orally bioavailable inhibitor of the phosphatidylinositide 3-kinase (PI3K). It selectively inhibits the delta isoform of PI3K (p110δ) and prevents the activation of the PI3K/AKT signaling pathway with an IC50 of 3.5 nM. It functions as an antineoplastic agent.

Zandelisib(ME-401; PWT-143) is an orally bioavailable inhibitor of the phosphatidylinositide 3-kinase (PI3K). It selectively inhibits the delta isoform of PI3K (p110δ) and prevents the activation of the PI3K/AKT signaling pathway with an IC50 of 3.5 nM. It functions as an antineoplastic agent.

Zanidatamab (Anti-ERBB2 / HER2 / CD340) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). It has anti-tumour activity and can be used in treatment of HER2-positive breast and gastric cancer. MW :144.96 KD.

Zanidatamab (Anti-ERBB2 / HER2 / CD340) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). It has anti-tumour activity and can be used in treatment of HER2-positive breast and gastric cancer. MW :144.96 KD.

Zanidatamab (Anti-ERBB2 / HER2 / CD340) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). It has anti-tumour activity and can be used in treatment of HER2-positive breast and gastric cancer. MW :144.96 KD.

Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD.

Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD.

Zansecimab (Anti-ANGPT2) is a humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2) with potential anti-angiogenic activity. MW: 145.74 kD.

Zaocys Dhumnades Extract is derived from the dried body of adult Zaocys dhumnades, which is effective in the dispelling cold or wind, dredging meridians, sedation, and mainly used in the treatment of rheumatism, leg and hand’s numb, paraplegic, twitching spasms, as well as tetanus, leprosy acariasis in China and other Asian countries.

ZAP-180013 is a inhibitor of zeta-chain-associated protein kinase 70 (ZAP-70) with an IC50 of 1.8 μM.

ZAP-180013 is a inhibitor of zeta-chain-associated protein kinase 70 (ZAP-70) with an IC50 of 1.8 μM.

Zapnometinib (PD0184264, ATR-002), an major active metabolite of CI-1040, is a novel MEK inhibitor with an IC50 of 5.7 nM.

Zapnometinib (PD0184264, ATR-002), an major active metabolite of CI-1040, is a novel MEK inhibitor with an IC50 of 5.7 nM.

Zasocitinib( NDI-034858, TAK-279) is a TYK2 inhibitor, which is currently being investigated in a phase IIb trial for moderate-to-severe plaque psoriasis.

Zasocitinib( NDI-034858, TAK-279) is a TYK2 inhibitor, which is currently being investigated in a phase IIb trial for moderate-to-severe plaque psoriasis.

Zasocitinib( NDI-034858, TAK-279) is a TYK2 inhibitor, which is currently being investigated in a phase IIb trial for moderate-to-severe plaque psoriasis.

Zeaxanthin, the carotenoid alcohol participates in the xanthophyll cycle, activates the extrinsic apoptosis pathwaywhich induces apoptosis on uveal melanoma cells with IC50 value 40.8 µM.